US Patent No: 8,039,009 - Analytics, PDF, Full Text and PAIR Access

Number of patents in Portfolio can not be more than 2000

Modified release formulations of memantine oral dosage forms

ALSO PUBLISHED AS: 20060051416

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
FOREST LABORATORIES HOLDINGS LIMITEDHAMILTON50

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Abramowitz, Wattanaporn West Windsor, NJ 16 39
Dedhiya, Mahendra G Dublin, OH 50 81
Mahashabde, Shashank Kendall Park, NJ 17 23
Periclou, Antonia Jersey City, NJ 15 54
Rao, Niranjan Belle Mead, NY 17 54
Rastogi, Suneel K Island Park, NY 13 35

Cited Art Landscape

Patent Info (Count) # Cites Year
 
MERZ PHARMA GMBH & CO. KGAA (4)
5,061,703 Adamantane derivatives in the prevention and treatment of cerebral ischemia 41 1990
5,382,601 Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof 31 1993
6,034,134 1-Amino-alkylcyclohexane NMDA receptor antagonists 39 1998
6,071,966 1-amino-alkylcyclohexane NMDA receptor antagonists 9 1998
 
CHILDREN'S MEDICAL CENTER CORPORATION (3)
5,334,618 Method of preventing NMDA receptor-mediated neuronal damage 21 1992
5,506,231 Treatment of aids dementia, myelopathy and blindness 9 1993
5,614,560 Method of preventing NMDA receptor-mediated neuronal damage 31 1995
 
FOREST LABORATORIES HOLDINGS LIMITED (3)
2006/0002,999 Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane 11 2005
2007/0065,512 MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE 16 2006
2009/0247,644 MEMANTINE FORMULATIONS 1 2009
 
GATX VENTURES, INC. (2)
5,582,837 Alkyl-substituted cellulose-based sustained-release oral drug dosage forms 99 1995
5,972,389 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter 140 1996
 
ADAMAS PHARMACEUTICALS, INC. (1)
2006/0142,398 Method and composition for adminstering an NMDA receptor antagonist to a subject 18 2005
 
ASTRAZENECA AB (1)
6,479,553 Use of certain affinity NMDA antagonists as antidepressants 16 2000
 
DepoMed Systems, Inc. (1)
5,007,790 Sustained-release oral drug dosage form 151 1989
 
KENRICO LTD (1)
6,413,556 Aqueous anti-apoptotic compositions 7 2000
 
MAYNE PHARMA INTERNATIONAL PTY LTD (1)
6,194,000 Analgesic immediate and controlled release pharmaceutical composition 82 1998
 
MERZ + CO. GMBH & CO. (1)
4,273,774 Central nervous system compositions and method 21 1979
 
NEUROMOLECULAR, INC. (1)
2005/0245,617 Methods and compositions for the treatment of CNS-related conditions 17 2005
 
PANORAMA RESEARCH, INC. (1)
6,444,702 Aminoadamantane derivatives as therapeutic agents 18 2000
 
Other [Check patent profile for assignment information] (1)
2004/0102,525 Compositions and methods of treating neurological disease and providing neuroprotection 34 2003

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
ADAMAS PHARMACEUTICALS, INC. (1)
8,741,343 Method of administering amantadine prior to a sleep period 0 2010

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Apr 18, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 18, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 18, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00